Financial Analysis: Neuphoria Therapeutics (NEUP) versus The Competition

Neuphoria Therapeutics (NASDAQ:NEUP) is one of 618 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare Neuphoria Therapeutics to similar companies based on the strength of its valuation, earnings, profitability, risk, analyst recommendations, institutional ownership and dividends.

Insider & Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Neuphoria Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	0	2	0	2.33
Neuphoria Therapeutics Competitors	5450	12006	37302	1132	2.61

Neuphoria Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 582.93%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 66.89%. Given Neuphoria Therapeutics’ higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than its peers.

Profitability

This table compares Neuphoria Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-1.95%	-1.47%
Neuphoria Therapeutics Competitors	-1,434.05%	-643.73%	-28.40%

Valuation and Earnings

This table compares Neuphoria Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	-$370,000.00	0.77
Neuphoria Therapeutics Competitors	$959.30 million	-$45.98 million	10.41

Neuphoria Therapeutics’ peers have higher revenue, but lower earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Neuphoria Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics’ peers have a beta of 0.97, suggesting that their average share price is 3% less volatile than the S&P 500.

Summary

Neuphoria Therapeutics peers beat Neuphoria Therapeutics on 8 of the 13 factors compared.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.